Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1089/jir.2020.0187 http://scihub22266oqcxt.onion/10.1089/jir.2020.0187 33885337!ä!33885337 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Interferon+Cytokine+Res 2021 ; 41 (4): 149-152 Nephropedia Template TP {{tp|p=33885337|t=2021. Linkage of Lambda Interferons in Protection Against Severe COVID-19 |pdf=|usr=}}{{33885337}} gab.com Text Linkage of Lambda Interferons in Protection Against Severe COVID-19 JO: J Interferon Cytokine Res http://www.kidney.de/pget.php?&tw=1&pmid=33885337 #FOAvip The most recently discovered interferon (IFN) family, type III IFNs or lambda IFNs (IFN-lambdas) are caused by viral infection and act in mucosal barriers, such as the respiratory tract. In this study, we assessed the serum levels of IFN-lambdas in new coronavirus disease-2019 (COVID-19) patients. Sixty-four COVID-19 patients were enrolled in this study. All cases were divided into the intensive care unit (ICU) and non-ICU groups according to their symptoms. Fourteen samples of healthy controls were also included. The serum levels of IFN-lambda1 and IFN-lambda2 were analyzed by specific enzyme-linked immunosorbent assay (ELISA) kits. The concentrations of IFN-lambda1 and IFN-lambda2 induced in the serum of non-ICU patients (836.7 +/- 284.6 and 798.8 +/- 301.5 pg/mL, respectively) were higher than found in ICU patients (81.57 +/- 34.25 and 48.32 +/- 28.13 pg/mL, respectively) (P = 0.004 and P = 0.006, respectively) and healthy controls (85.57 +/- 33.63 and 65.82 +/- 21.26 pg/mL, respectively) (P = 0.03 and P = 0.04, respectively). Meanwhile, no significant differences were found in the concentration of both cytokines between the ICU patients and healthy controls. We conclude that higher levels of IFN-lambdas are associated with decreased clinical manifestations in COVID-19 patients. These cytokines could be a promising therapeutic agent to avoid the overwhelming consequences of COVID-19. Twit Text FOAVip Linkage of Lambda Interferons in Protection Against Severe COVID-19 ????J Interferon Cytokine Res http://www.kidney.de/pget.php?&tw=1&pmid=33885337 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33885337 #FOAvip English Wikipedia <ref>{{Cite pmid|33885337}}</ref> Linkage of Lambda Interferons in Protection Against Severe COVID-19 #MMPMID33885337 Shahbazi M; Amri Maleh P; Bagherzadeh M; Moulana Z; Sepidarkish M; Rezanejad M; Mirzakhani M; Ebrahimpour S; Ghorbani H; Ahmadnia Z; Javanian M; Bayani M; Mohammadnia-Afrouzi M J Interferon Cytokine Res 2021[Apr]; 41 (4): 149-152 PMID33885337show ga The most recently discovered interferon (IFN) family, type III IFNs or lambda IFNs (IFN-lambdas) are caused by viral infection and act in mucosal barriers, such as the respiratory tract. In this study, we assessed the serum levels of IFN-lambdas in new coronavirus disease-2019 (COVID-19) patients. Sixty-four COVID-19 patients were enrolled in this study. All cases were divided into the intensive care unit (ICU) and non-ICU groups according to their symptoms. Fourteen samples of healthy controls were also included. The serum levels of IFN-lambda1 and IFN-lambda2 were analyzed by specific enzyme-linked immunosorbent assay (ELISA) kits. The concentrations of IFN-lambda1 and IFN-lambda2 induced in the serum of non-ICU patients (836.7 +/- 284.6 and 798.8 +/- 301.5 pg/mL, respectively) were higher than found in ICU patients (81.57 +/- 34.25 and 48.32 +/- 28.13 pg/mL, respectively) (P = 0.004 and P = 0.006, respectively) and healthy controls (85.57 +/- 33.63 and 65.82 +/- 21.26 pg/mL, respectively) (P = 0.03 and P = 0.04, respectively). Meanwhile, no significant differences were found in the concentration of both cytokines between the ICU patients and healthy controls. We conclude that higher levels of IFN-lambdas are associated with decreased clinical manifestations in COVID-19 patients. These cytokines could be a promising therapeutic agent to avoid the overwhelming consequences of COVID-19. |*COVID-19/blood/prevention & control[MESH] |Adult[MESH] |Aged[MESH] |Enzyme-Linked Immunosorbent Assay[MESH] |Female[MESH] |Humans[MESH] |Interferons/*blood[MESH] |Interleukins/*blood[MESH] |Male[MESH] |Middle Aged[MESH]Linkage of Lambda Interferons in Protection Against Severe COVID-19 (epmc).pdf DeepDyve Pubget Overpricing